Pacira BioSciences, Inc. (PCRX) Research
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Market snapshot
- Symbol
- PCRX
- Price
- $22.33
- Day change
- -1.37%
- Market cap
- $878.4M
- P/E ratio
- 175.85x
- 52-week range
- 18.8-27.64
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Next earnings
- in 2 months
- Analyst price target
- $32.00
Peer companies
Recent insider activity
- Hirawat Samit — A-Award (10891 shares) on 2026-06-10
- Hirawat Samit — A-Award (6405 shares) on 2026-06-10
- RIKER LAUREN — S-Sale (6115 shares) on 2026-06-11
- CHRISTIE CHRISTOPHER — A-Award (6405 shares) on 2026-06-10
- CHRISTIE CHRISTOPHER — A-Award (10891 shares) on 2026-06-10
Open Pacira BioSciences, Inc. (PCRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.